Patrick Kobett
Family Medicine · Arlington, TXNPI 1376503896
Payments from drug & device makers
Across 126 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$376
- Novo Nordisk$224
- GSK$188
- Lilly USA, LLC$168
- Johnson & Johnson$124
- Pfizer$116
- plus $743 from 20 others
What the payments were for
- Food & beverage$1,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $376 |
| Novo Nordisk | 15 | $224 |
| GSK | 12 | $188 |
| Lilly USA, LLC | 9 | $168 |
| Johnson & Johnson | 7 | $124 |
| Pfizer | 7 | $116 |
| Boehringer Ingelheim | 6 | $91 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Abbott | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 5 | $60 |
| Amgen | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Astellas Pharma US Inc | 4 | $53 |
| Dexcom, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $30 |
| AstraZeneca | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Insulet Corporation | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Medtronic | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$1,939 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $27,931 |
| JardianceEmpagliflozin | 16 | $19,248 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $975 |
| Gabapentin | 35 | $836 |
| Omeprazole | 18 | $533 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $527 |
| Atorvastatin Calcium | 59 | $477 |
| Duloxetine Hcl | 12 | $441 |
| Pantoprazole Sodium | 43 | $415 |
| Levothyroxine Sodium | 42 | $395 |
| Pravastatin Sodium | 35 | $366 |
| Bupropion XlBupropion Hcl | 13 | $345 |
| Amlodipine Besylate | 44 | $337 |
| Glimepiride | 30 | $312 |
| Losartan Potassium | 33 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $224 | $27,93116 claims |
| Boehringer IngelheimJardiance | $91 | $19,24816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.